Research You Can Use: A Strategy Toward Hepatitis C Elimination

Updated: Oct 1, 2021


Supporting Opioid Substitution Treatment and Hepatitis C Treatment in People Who Inject Drugs: A Strategy Toward Hepatitis C Elimination


Supported by an educational grant from Gilead Sciences, Inc.

Mark S. Gold, MD

Prevalence of infectious diseases is substantially higher among patients with substance use disorders (SUDs). There are factors associated with drug use that increase the risk of infections, such as sharing needles and injecting supplies, presence of contaminants in drugs and drug use–related paraphernalia, risky behaviors associated with drug use, immune suppression secondary to chronic drug use, poverty, and homelessness. Persons with SUDs have low rates of health care utilization and may miss opportunities for early diagnosis and care of infectious complications of substance use. When infectious diseases are comorbid with drug use, they are associated with substantial morbidity and mortality and result in significant health care costs [1,2].


The National Notifiable Diseases Surveillance System of the Centers for Disease Control and Prevention (CDC) has reported steady increases in hepatitis C virus (HCV) infections to 2.8 cases per 100,000 population in 2019, above the target of 2.1 per 100,000 population. This continued increase in HCV infections is fueled by injection drug use (IDU) among individuals age 18-40 [3]. The established goal of the National Hepatitis Progress Report is 1.7 cases per 100,000 population by 2025 [4]. Contributing to the risk among young people who inject drugs (PWID) is in part due to the high likelihood of sharing and/or reusing injection equipment and the decreased likelihood of access to harm reduction services and health care compared to older cohorts of PWID [5-7]. The HCV treatment cascade in young PWID illustrates gaps that hinder HCV elimination. Among 3,748 young PWID in San Francisco, 66.4% were diagnosed with HCV, but only 9.1% had initiated treatment, and 50% had a confirmed cure. Unfortunately, no single solution can change the course of rising HCV infections. HCV elimination requires changes to public policy as well as improved access to and navigation of health care, mental health, and harm reduction services, community-level programs, and education, in addition to a reduction in stigma associated with substance use [3].




Treatment of opioid use disorder (OUD) with opioid substitution treatment (OST) has been shown to reduce the transmission of HCV among PWID [8-13]. A number of sites around the United States have successfully co-located treatment for HCV and OUD. Martinez and colleagues have reported positive outcomes at La Bodega in Buffalo, New York, integrating medical and addiction services through a hybrid model of outreach, referral, co-localization of direct-acting antiviral agents (DAAs) and OST services, and telemedicine [14-16]. Rojas and colleagues assessed a decentralized hub and spoke model for HCV treatment administered in a Federally Qualified Health Center (FQHC) in San Diego, California, and reported successful treatment and retention among 1,261 patients treated by a multidisciplinary team of primary care physicians, nurse practitioners, and infection disease specialist supported by patient navigators [17]. However, strategies and programs like these have not been widely implemented.


It has been hypothesized that OST may increase engagement in HCV care among PWID. In the recent publication Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis, Grebely and colleagues conducted a systematic review of existing literature to evaluate the association between OST and HCV testing and treatment uptake, and to assess the association between OST and adherence, treatment completion, and sustained virologic response (SVR) following treatment among PWID [18]. The review entailed a total of 9,877 HCV cascade of care studies from electronic databases. After criteria for inclusion/exclusion were applied (e.g., study type, wrong populator or comparator, misaligned outcomes, duplicates), 22 studies were included in the meta-analysis.


Impact of OST on HCV Antibody Testing

  • Random-effect meta-analysis of estimates demonstrated that having ever received OST was associated with increased odds of having ever received HCV antibody testing.

  • Recent exposure to OST was associated with increased odds of having ever received HCV antibody testing.

  • Recent exposure to OST was associated with increased odds of recent HCV antibody testing.

Impact of OST on HCV RNA Testing

  • Having ever received OST was associated with increased odds of having ever received HCV RNA testing.

  • Recent exposure to OST was associated with increased odds of having ever received HCV RNA testing.

  • Recent exposure to OST was associated with increased odds of recent HCV RNA testing.

Impact of OST on HCV Treatment Uptake

  • The association of having ever received OST and having ever received any HCV treatment was not statistically significant.

  • Recent exposure to OST was associated with increased odds of having ever received any HCV treatment.

  • When considering only studies from the recent DAA era, recent exposure to OST was associated with increased odds of recent DAA HCV treatment.

Impact of OST on HCV Treatment Completion and SVR

  • The proportion of people who had initiated and completed HCV treatment was between 65% and 100%, with between 64% and 94% achieving SVR. However, when pooling data from studies that measured the impact of recently receiving OST on HCV treatment completion or achievement of SVR, there was no impact [18].


The mechanism behind the associations between OST and HCV treatment are multifactorial, relating to the intersection of system-, provider-, social-, and patient-level factors. Engagement of PWID in the healthcare system is essential for medical care, mental health services, and harm reduction. Individuals receiving OST often establish a trusting relationship with their health care professional (HCP), through routine interaction, which promotes education and opportunities for testing and treatment [18].




Stigma related to substance use can perpetuate negative attitudes toward PWID, creating barriers to seeking treatment and successful treatment. Williams and colleagues found that perceptions of substance-use stigma were associated with a higher likelihood of HCV infection in young PWID in suburban populations [7]. Bias among clinicians related to substance use can contribute to a treatment-averse mindset and to flawed clinical care, including failure to implement proven methods of HCV treatment. A shift in language and terms that medicalize substance use is one key component to reduce associated stigma and psychosocial burden [19].


Established biases and perceptions among HCPs about adherence to HCV treatment in PWID are not supported by the data. The HEpatitis C Real Option (HERO) Study comparing 12-week SVR in active PWID showed a positive HCV cascade of care in 83.6% of patients with HCV infection treated with sofosbuvir/velpatasvir, with 69.7% completing treatment and 56.2% achieving SVR. In the cohort assisted by patient navigation, 73.4% were adherent to treatment [20]. Among 103 persons in the SIMPLIFY trial with recent IDU treated with sofosbuvir/velpatasvir for 12 weeks, 94% achieved HCV cure with no virologic failures and 96% had ≥ 90% adherence [21]. Similar results were seen in pooled data of patients treated with glecaprevir/pibrentasvir (n = 2,256). In patients prescribed OST and reported IDU in the past 12 months, treatment adherence was 98% in the OST group and 99% among PWID not receiving OST. These data support treatment of PWID for HCV infection [22].


Reinfection with HCV among PWID is another concern that may interfere with treatment. Yet a recent meta-analysis of 36 studies reflecting 6,311 person-years follow-up found that the overall reinfection among people with recent drug use (injecting or non-injection) was 5.9/100 person years (95% confidence interval [CI]: 4.1-8.5). Among people receiving OST with no recent drug use, HCV reinfection was 1.4/100 person-years (95% CI: 0.8-2.6) [23].


Perceptions, bias, and stigma have the power to interfere with treatment and prevention strategies for HCV. Data support the treatment of PWID. Findings from the previously mentioned Grebely et al review demonstrate that recent OST use is associated with improvements in HCV testing and treatment uptake, supporting the integration of HCV services in drug treatment centers [18].


Click here to collect CME/CE credit.



Dr. Mark S. Gold is a teacher of the year, translational researcher, author, mentor and inventor best known for his work on the brain systems underlying the effects of opiate drugs, cocaine and food.




References

1. Kolla BP, Oesterle T, Gold M, et al. Infectious diseases occurring in the context of substance use disorders: a concise review. J Neurol Sci. 2020;411:116719. 2020 Jan 31. [Epub ahead of print]. PMID: 32070807.

2. Oesterle TS, Thusius NJ, Rummans TA, Gold MS. Medication-assisted treatment for opioid-use disorder. Mayo Clin Proc. 2019;94(10):2072-2086.

3. Centers for Disease Control and Prevention [CDC]. Viral hepatitis surveillance—United States, 2019. CDC Website. https://www.cdc.gov/hepatitis/statistics/2019surveillance/index.htm. Published July 2021. Accessed September 27, 2021.

4. Centers for Disease Control and Prevention [CDC]. National progress report 2020. CDC Website. https://www.cdc.gov/hepatitis/policy/npr/2020/NationalProgressReport2020.htm. Last reviewed June 8, 2021. Accessed September 27, 2021.

5. Bryant J. A study of young people who inject drugs: an opportunity to decrease high risk injecting by improving knowledge about hepatitis C prevention. Vulnerable Child Youth Stud. 2014;9(2):104-113.

6. Novelli LA, Sherman SG, Havens JR, et al. Circumstances surrounding the first injection experience and their association with future syringe sharing behaviors in young urban injection drug users. Drug Alcohol Depend. 2005;77(3):303-309.

7. Williams LD, Mackesy-Amiti ME, Latkin C, Boodram B. Drug use-related stigma, safer injection norms, and hepatitis C infection among a network-based sample of young people who inject drugs. Drug Alcohol Depend. 2021;221:108626.

8. Facente SN, Patel S, Hecht J, et al. Hepatitis C care cascade for 3 populations at high risk: low-income trans women, young people who inject drugs, and men who have sex with men and inject drugs. Clin Infect Dis. 2021;73(6):e1290-e1295.

9. Tsui JI, Evans JL, Lum PJ, et al. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med. 2014;174:1974-1981.

10. Martin NK, Hickman M, Hitchinson SJ, et al. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis. 2013;57(suppl 2):S39-S45.

11. Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis. 2011;204:74-83.

12. MacArthur GJ, van Velzen E, Palmateer BM, et al. Interventions to prevent HIV and hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy. 2014;25:34-52.

13. Kattakuzhy S, Rosenthal. To eliminate hepatitis C in people who inject drugs, stop ignoring drug-user health. Clin Infect Dis. 2021;73(1):e119-e121.

14. Martinez A. The Liver Meeting 2020 (American Association for the Study of Liver Diseases [AASLD]). Boston, MA. Abstract 0476.

15. Martinez A. International Liver Congress, European Association for The Study of Liver 2020. London, England. Abstract 2267.

16. Martinez A. The Liver Meeting, 2019 (American Association for the Study of Liver Diseases [AASLD]). Boston, MA. Abstract 1608.

17. Rojas SA, Godino JG, Northrup A, et al. Effectiveness of a decentralized hub and spoke model for the treatment of hepatitis C virus in a federally qualified health center. Hepatol Commun. 2021;5(3):412-423.

18. Grebely J, Tran L, Degenhardt L, et al. Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis C infection among people who inject drugs: a systematic review and meta-analysis. J Clin Infect Dis. 2021;73(1):e107-e118.

19. Volkow ND, Gordon JA, Koob GF. Choosing appropriate language to reduce the stigma around mental illness and substance use disorders. Neuropsychopharmacology. 2021. Doi:10.1038/s41386-021-01069-4. [Epub ahead of print].

20. Litwin AH, Lum PJ, Taylor LE, et al. A multisite randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: the HERO study – hepatitis C real options. Presented at: American Association for the Study of Liver Diseases [AASLD] – virtual. November 11-16, 2020. https://www.natap.org/2020/AASLD/AASLD_37.htm.

21. Grebely J, Dalgard O, Conway B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol. 2018;3(3):153-161.

22. Grebely J, Dore GJ, Alami NN, et al. Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy. Int J Drug Policy. 2019;66:73-79.

23. Hajarizadeh B, Cunningham EB, Valerio H, et al. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: a meta-analysis. J Hepatol. 2020;72(4):643-657.